Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 7Colonic Neoplasms 5Rectal Neoplasms 4Breast Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

entinostat 1cediranib 1carboxyamido-triazole 1Thalidomide 1Tamoxifen 1Radiotherapy 1Paclitaxel 1Immunologic Techniques 1Fentanyl 1Erlotinib Hydrochloride 1Doxorubicin 1Docetaxel 1Cisplatin 190Y-octreotide, DOTA-Tyr(3)- 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × cediranib × Thoracic × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡